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Abstract
Smart drug delivery systems are very popular drug delivery systems for treatment to
common disease such as gene therapy, heart disease, cancer therapy, and neuropathy.
Neuropathy is the most common chronic complication of diabetes that is associated with
especially loss of peripheral nerve fibers. Hyperglycemia, insulin deficiency and dyslipi‐
demia largely affect the development and progression of diabetic neuropathy. Several
metabolic disruptions including altered protein kinase C, elevated polyol pathway activi‐
ty, oxidative stress, the formation of advanced glycation and lipoxidation end products,
and various pro-inflammatory changes directly affect neural tissue and cause neurodege‐
nerative changes in diabetes. The therapeutic interventions of these metabolic pathways
have a limited success to relieve the symptoms of diabetic neuropathy. This review em‐
phasizes on the pathogenesis of neurovascular changes, presently available therapeutic
approaches future directions for the management of diabetic neuropathy and related new
drug delivery systems.
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1. Introduction
Diabetes mellitus (DM) is the most common disease, causing neuropathy worldwide. In the
last century, although we have more information about clinical forms of diabetic neuropathy,
sufficient knowledge about the pathophysiology of neuropathy could not be reached.
Diabetic neuropathy is defined as a peripheral neuropathy that may occur in clinical and
subclinical levels and develops in the DM ground in the absence of other peripheral neuro‐
pathy factors.
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While neuropathy is present at the time of diagnosis in 10% of diabetic patients, this rate
reaches to 50% at the end of 20 years. There are studies, which demonstrate that neuropathy
starts within 9 years after the diagnosis of Type 2 diabetes. It may include manifestations
associated with somatic and/or autonomic parts of peripheral nervous system.
The relationship between DM and neuropathy is known for over 100 years. The classification
was first suggested by Leyden in 1893 with hyperesthetic (painful), paralytic (motor), and
ataxic forms. Large sensory, small sensory, autonomic, and motor fibers may be affected by
neuropathy. The findings may be symmetrical or asymmetrical. The most common form of
neuropathy is distal sensorimotor polyneuropathy. The most common mononeuropathy is
carpal tunnel syndrome (CTS). However, the recognition of some rare types such as diabetic
lumbosacral radiculoplexus neuropathy that may cause pain and weakness is important for
the reduction of morbidity.
The annual incidence of neuropathy is closely associated with the known duration of diabetes.
Height, maximum body mass index, smoking, systolic and diastolic blood pressures, estradiol
level, and cholesterol level were not found different in those with neuropathy and without
neuropathy.
Given that diabetes is estimated to affect about 246 million people worldwide, it may be
calculated that there are 20–30 million people suffering from symptomatic diabetic neuropa‐
thy. This number is thought to double by 2030 [1].
The contribution of neuropathy to mortality is very low. Disability was reported to be in 44%
of the patients with Type 1 DM and definite neuropathy, and partial restriction was reported
to be in activity in 74% of those with Type 2 DM and sensory neuropathy [2,3]. Hypertension,
independent of duration of diabetes, has been shown to be the most important factor in the
development of neuropathy in a study of Pittsburg Epidemiology of Diabetes Complications
(EDC) about the effects of hypertension, height, and smoking on the incidence of distal
symmetric polyneuropathy in long-lasting and poorly controlled diabetic patients [4].
Diabetic cardiac autonomic neuropathy is a serious complication seen in one fourth of Types
1  and  2  diabetic  patients.  It  results  in  high  mortality  and  silent  myocardial  ischemia.
Autonomic dysfunction has been shown as the reason for having the risk of cardiovascular
disease and sudden death in patients with Type 2 diabetes. The activation of cytokines is the
indicator of the inflammation in patients with diabetes. These changes have been associat‐
ed with the sympathetic–vagal balance disorders. Patients have complaints of orthostatic
hypotension, exercise intolerance, lack of enhanced stability during surgery, silent myocar‐
dial infarction, and ischemia. The use of heart rate change (HRV) and Valsalva maneuver has
been reported in the diagnosis of cardiac autonomic neuropathy [5]. An over activation of
the sympathetic  system and the activation of  inflammatory cascade were observed with
hyperleptinemia and lack of adiponectin in case of sleep apnea that is common in diabetes
and metabolic syndrome. Ultimately, negative effects seen in the autonomic nervous system
as a result of cardiovascular function impairment give rise to higher morbidity and mortali‐
ty in diabetic patients [6].
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2. Pathogenesis of diabetic neuropathy
Diabetic neuropathy develops as a result of involvement of different nerves in varying degrees
in different individuals. The actual lesions were observed to be in peripheral nerve axons in
histopathological studies conducted in patients with diabetic neuropathy. Schwann cells,
perineural cells, and endoneurial vascular structures are also affected by neuropathies.
Wallerian degeneration, segmental and paranodal demyelination, and endoneurial connective
tissue proliferation occurred with the loss and damage of thick and thin myelinated nerve
fibers. Severe axonal atrophy, widespread fiber loss, and nodal and paranodal changes develop
in Type 1 diabetes. Structural changes in Type 2 diabetes are milder. Mild axonal atrophy,
localized fiber loss, segmental demyelination, and Wallerian degeneration are observed.
Primary axonal changes are more evident in Type 1 diabetes, and primer Schwann cell
pathology is more evident in Type 2 diabetes.
There is a close relationship between the degree and duration of hyperglycemia and the
development of diabetic neuropathy. Development of neuropathy can be delayed or prevented
through good metabolic control. The development of clinical diabetic neuropathy was
observed to be decreased by 69% in the primary prevention group and 57% in the secondary
intervention group after 5 years of intensive diabetes treatment in those with Type 1 diabetes
in a study. Six separate factors associated with each other are thought to have an important
role in the pathogenesis of DM.
Several mechanisms have been suggested in the pathogenesis of diabetic neuropathy. These
are metabolic processes which involve direct nerve damage, endoneurial microvascular
damage, autoimmune inflammation, and reduced neurotrophic support.
Epidemiological studies showed that the duration and severity of hyperglycemia are major
risks in the development of neuropathy in patients with Types 1 and 2 DM [7]. Common
opinion on the development of DSP (diabetic symmetric polyneuropathy) is that starting of
the early nerve damage from the short, thin, myelinated A-delta fibers and unmyelinated C
type of nerve fibers. The gold standard to assess the morphological changes in the short nerve
fibers is a skin biopsy. However, not providing information about the nerve function, cost, and
superficiality and being of no use in all patients with Type 1 diabetes limit this technique. The
presence of a valid clinical practice, which identifies early short fiber disorder by using imaging
techniques, was reported recently [8].
2.1. Metabolic factors
2.1.1. Increased glycosylation end products
The glycosylation of the plasma and tissue proteins plays a major role in diabetic microvascular
complications by causing the formation of advanced glycation end products (AGEs). Excess
glucose combines with amino acids on circulating and tissue proteins in the presence of chronic
hyperglycemia. This non-enzymatic process initially leads to the formation of reversible early
glycosylation end products and, later, to irreversible advanced glycosylation end products.
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Advanced glycosylation products change their function by modifying intracellular proteins
and extracellular matrix proteins that interact with extracellular integrins. AGE precursors
modify plasma proteins by binding IGU receptors RAGE (receptor of advanced glycation end
products) in mesangial endothelial cells, microglia, and macrophages. Thus, they initiate the
production of reactive oxygen species (ROS). The activation of NF-κB initiates proinflamma‐
tory gene expression. Cytokines and growth factors are expressed by macrophages and
mesangial cells [9]. Significantly increased serum concentrations of AGEs have been reported
to lead to the development of diabetic complications by their proinflammatory effect in diabetic
patients. The other effects of AGEs are increasing in vascular permeability, procoagulant
activity, adhesion molecule expression, and monocyte invasion [10].
Sorbitol: Glucose, which enters into the cell, is metabolized to sorbitol by the enzyme aldose
reductase. Glucose is converted to sorbitol and fructose by the enzyme aldose reductase due
to excessive activation of this pathway owing to hyperglycemia. The accumulation of sorbitol
in the cell results in the reduction of myoinositol and taurine, and this leads to decrease in Na–
K adenosine triphosphatase (ATPase) activity and reduction of nerve conduction velocity. As
a result of the accumulation of sorbitol in the cell, nicotinamide adenine dinucleotide phos‐
phate (NADPH) associates with reduced cell metabolism, increased cell osmolarity, and
decreased intracellular myoinositol, and the cell has a tendency to oxidative stress. Hypergly‐
cemia may cause an increase in glucose in some intracellular tissues (such as nerves, lenses,
kidneys, and blood vessels) that do not require insulin for glucose transport. Sorbitol and
fructose that increase in these tissues cause two undesirable effects. First, accumulated sorbitol
and fructose lead to an influx of water and eventually to osmotic cell injury by increasing
intracellular osmolarity. Second, sorbitol accumulation results in reduction in the myoinositol
content and impairment of Na–K ATPase. This mechanism may be responsible for the damage
in Schwann cells and retinal capillary pericytes and causes peripheral neuropathy and
microaneurysms. Although the relationship between oxidative stress and diabetic retinopathy,
nephropathy, and neuropathy is well known, the therapeutic efficacy of many antioxidants
(including aldose reductase inhibitors, vitamins C and E) tested in clinical trials has not yet
been established.
Hexosamine: Uridine diphosphate-N-acetyl glucosamine (UDPGlcNAc), which regulates
transcription factors needed for normal cell functions, is produced in hexosamine pathway.
Excess glucose is replaced with glycolytic mediators in hexosamine pathway, and thus, glucose
flux to hexosamine pathway results in cell injury and increased oxidative stress. The effects of
aldose reductase inhibitors in animal models were found to be more effective than clinical
trials. One of the reasons is being lower dose used in clinical trials compared with dose used
in animal studies.
Protein kinase C: Excess glucose is converted to diacylglycerol that activates protein kinase C.
The activation of protein kinase C increases in contractility, permeability, and vascular cell
proliferation and enhances the production of extracellular matrix and cytokines. Thus,
vasoconstriction and nerve ischemia occur. These neurovascular changes also contribute to
diabetic neuropathy. Diacylglycerol-protein kinase C activation was also shown to be associ‐
ated with many vascular abnormalities in retinal, renal, and cardiovascular tissues in diabetes
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and insulin resistance period. High glucose enhances ROS formation by causing NF-κB
activation in endothelial cells. This condition may be prevented by PKC (protein kinase C)
inhibitors [9].
Poly (ADP-ribose) polymerase: Nuclear enzyme poly (ADP-ribose) polymerase (PARP) becomes
activated in response to high glucose. This enzyme helps to repair DNA by separating
nicotinamide adenine dinucleotide (NAD+) into the remains of nicotinamide and adenine
ribose. Over activation of PARP results in increased free radical formation, harmful changes
in gene transcription, protein kinase C activation, and increased AGEs.
2.2. Oxidative stress
As mentioned above, hyperglycemia causes accumulation of ROS and oxidative stress
eventually by interacting with many different ways. The free radical is a chemical species
usually having very reactive unpaired electron in the molecular or atomic orbit. Although free
radical reactions are necessary for defense mechanisms of immune system cells including
neutrophils and macrophage, the overproduction of free radicals results in tissue injury and
cell death. Free radicals affect all essential components of cells such as lipids, proteins, DNA,
and carbohydrates and lead to the deterioration of their structure. The formation and elimi‐
nation rates of free radicals are in balance in the organism, which are known as oxidative
balance. The organism is not affected by free radicals as long as oxidative stability is provided.
Studies in which the relationship between diabetes and diabetes complications and the ROS
are shown, it is highlighted that tissue injury due to non-enzymatic glycation, metabolic stress
caused by changes in energy metabolism, sorbitol path activity, hypoxia, and ischemia–
reperfusion, increases the production of free radical and alters the antioxidant defense system.
There are studies, which support that the formation of free radical is a direct result of hyper‐
glycemia, as well as experimental trials that show that the formation of free radical starts when
the endothelial and smooth muscle cells were incubated in the medium containing high
concentrations of glucose. Hyperglycemia-mediated ROS production occurs via three mech‐
anisms. The first mechanism is the auto-oxidation of glucose and superoxide production.
Glucose is converted to reactive keto aldehydes and superoxide anion in the presence of a
transition element. The chain of reactions results in the transformation of superoxide radical
into extremely reactive hydroxyl radical via hydrogen peroxide. The intracellular glucose
oxidation leads to the release of NADH. NADH is used for providing needed energy for ATP
production by the oxidative phosphorylation way in the respiratory chain. Superoxide radical
is released during this reaction in the respiratory chain. The production of superoxide radicals
increases in this way in the presence of high glucose concentration. Mitochondrial respiratory
chain is the main intracellular source of ROS production. It is considered that superoxide
radical occurs continuously during normal respiration chain of events. Recent studies showed
that much pathology in diabetes was associated with increased mitochondrial ROS production.
The second mechanism in the hyperglycemia-mediated ROS production is the glycation of
proteins and the formation of AGE products. When the proteins exposed to high glucose
concentrations, glucose leads to uncontrolled glycation reactions by binding to protein without
requiring the mediation of an enzyme. The glycated protein causes the formation of ROS by
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donating an electron to molecular oxygen. AGE products are formed after this non-enzymatic
reaction. Advanced glycosylation products lead to endothelial damage by increasing vaso‐
constriction via endothelin-1 and have the capacity to generate free radicals through complex
biochemical mechanisms. Toxic effects of AGEs also include being able to change the structure
and function of proteins and to induce oxidative stress with its receptors. The third mechanism
of ROS production is polyol pathway. High glucose concentration causes the sorbitol produc‐
tion by polyol pathway. As NADH is used for the activity of enzyme aldose reductase in this
pathway, intracellular NADH is consumed. NADH is required for converting oxidized
glutathione to reduced form and nitric oxide (NO) synthesis. Therefore, being active of the
sorbitol way and the absence of NADPH ultimately mean a limitation of cell’s antioxidant
capacity. The decrease in reduced glutathione and NO synthesis that has a function in
vasodilatation leads to the reduction of endoneurial blood flow, consequently endoneurial
hypoxia or ischemia. Due to this event, the damage occurs in neuronal cells, Schwann cells.
2.3. Vascular hypotheses
Swellings of the capillary vascular endothelial cells, thickening of the blood vessel wall, and
undergoing aggregation or fibrin and occlusion with platelets of capillary lumen were shown
in various studies. The sudden onset of clinical signs of focal neuropathies in diabetes supports
the vascular cause. Decrease in NO production, abnormalities in eicosanoid production, and
an increase in oxidative pathway lead to vasoconstriction in endoneurial microvascularization
and nerve hypoxia.
2.4. Immunological mechanisms
Autoantibodies against the sympathetic ganglia develop in patients with insulin-depend‐
ent diabetes. Endoneurial or epineural lymphocytic infiltration has been displayed in the
sural  nerve  biopsy  of  diabetic  patients.  Coexistence  of  diabetic  neuropathy  and chronic
inflammatory  demyelinating  polyneuropathy is  also  a  suggestive  finding of  immune or
cytotoxic factors [11].
2.5. Neurotrophic factors
Neurotrophins are proteins that ensure the growth, permanence, survival, and differentiation
into different specific populations of the neurons. There are studies, which show that impaired
neurotrophic support is involved in the pathogenesis of diabetic polyneuropathy. Since nerve
growth factor (NGF), a typical growth factor for the nerve, is needed for the survival and the
continuity of sympathetic and thin sensory nerve fibers, it was examined particularly well.
NGF also regulates the expression of the neuropeptides including calcium gene-related
peptide and substance P in sympathetic nerves and sensory neurons of dorsal root ganglion.
Retrograde axonal transport from target tissue to neuronal cell body is impaired in diabetes.
There is evidence, which shows that NGF expression is decreased in the skin, submandibular
glands, and the sympathetic ganglia in experimental diabetic neuropathy. NGF, when
administered to rats with streptozotocin-induced diabetes, prevented the protection of the
response to thermal painful stimuli (tail flick threshold) and the decrease in levels of neuro‐
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peptides including calcitonin gene-related peptide and substance P measured in the cervical
dorsal root ganglia. In diabetic autonomic neuropathy model, dystrophic changes in sympa‐
thetic ganglia following the administration of NGF indicate that there may be a different dosing
effect. Neurotrophin-3 (NT-3) supports the differentiation and survival of sensory neurons.
Decreased messenger RNA (mRNA) was shown in the leg muscle of NT-3 diabetic mice. Due
to their neurotrophic effect in the treatment of diabetic neuropathy in recent years, glucagon-
like peptide-1 (GLP-1) analogues (exendin-4) and peptides such as ghrelin were also found to
give successful results in animal models [12].
3. Diagnosis
Symptoms and physical examination findings should be evaluated together for an accurate
diagnosis of diabetic peripheral neuropathy (DPN). Standardization and easy application of
diagnostic methods are of great importance in terms of widespread availability. There is no
gold standard in the detection of presence of diabetic neuropathy. The San Antonio consensus
panel recommends performing at least one measurement in five different diagnostic catego‐
ries. These are symptom scoring, physical examination scoring, QST, cAFT, and EDS. The
neurological examinations of the patients often reveal gloves socks style sensory deficit,
hyporeflexia or areflexia, increase in vibration sense perception threshold, and moderate
atrophy and weakness particularly in intrinsic foot muscles.
Neuropathic pain is one of the most common symptoms that are ignored by both the patient
and the physician. Of the patients, 12.5% with painful DPN stated that they had never
mentioned the pain to the physicians before and 40% expressed that they had received no
treatment for pain. There are several questioning methods to query pain due to diabetic
polyneuropathy, but none of these methods have been accepted as the gold standard.
Visual Analog Scale (VAS) is an easy method applied by grading the pain on a scale of 1–10
by the patient. Another method of pain assessment is “The Leeds Assessment of Neuropathic
Symptoms and Signs” (LANSS) pain inquiry. Having a LANSS score of 12 or more is diagnostic
for neuropathic pain. The Michigan Neuropathy Screening Instrument is one of the other
commonly used interrogation methods, which is used in the diagnosis of neuropathic pain.
Neuropathy Disability Score (NDS), which was first developed by Dick for the standardization
of examination findings and correct interpretation of the findings and was simplified and
modified in the following years, is regarded as a reliable and easy method that does not require
experience in neurology. NDS = 0 is considered normal, NDS = 10 indicates maximum deficits,
and NDS = 6 or more indicates the risk of developing diabetic foot ulcers. Touch pressure,
vibration, hot–cold sensation, thermal pain, cold pain, and mechanical pain detection thresh‐
olds are tested in quantitative sensory testing.
The tests related to the vasomotor control, baroreceptor reflex, sudomotor function, pupil,
bladder, and bowel innervation are used in autonomic function tests. Electrodiagnostic studies
are one of the most common and objective methods used in the diagnosis of DPN. Weakness
of electrodiagnostic studies is not showing the early stages of thin fiber damage. Unmyelinated
Diabetic Neuropathy and Treatment Strategy – New Challenges and Applications
http://dx.doi.org/10.5772/62221
379
C fiber injury, the most common cause of painful DPN, does not provide any electrophysio‐
logical findings, but thick myelinated Aα and Aβ fiber involvements have EDS findings.
Staining of a 3-mm skin sample using protein gene product-9.5 allows the assessment of
intraepidermal thin fibers and early diagnosis of neuropathic damage. Although its sensitivity
is high, its use is limited because it is an invasive procedure [13].
4. Treatment in diabetic neuropathy
The prevention of occurrence of diabetic polyneuropathy or its definitive treatment is impos‐
sible.However, some measures that slow down the development of neuropathy, reduce the
severity of symptoms, and prevent the complications of neuropathy may be taken. Normal or
nearly normal blood glucose control of the patients should be provided. Keeping HGBA1C
below 7, cholesterol control, smoking cessation, alcohol reduction, avoiding obesity, and
having foot care delay the progression of neuropathy. When the structural link between
membrane ion channel dysfunction and axonal loss is assessed, neuropathy can be diagnosed
at an early stage with the detection of clinical biomarkers (biomarkers) that may identify the
presence of early changes in ion channel. Therefore, the opportunity arises to start treatment
without irreversible nerve damage [14].
4.1. Metabolic control
The most important treatment for the prevention of diabetic PNP (peripheral neuropathy) is
to control blood glucose. According to Diabetes Control and Complications Center (DCTT)
data, the reduction of neuropathy by 57% has been shown in Type 1 DM after 5 years of tight
blood glucose control.
4.2. Myoinositol
The addition of myoinositol to the diet was shown to improve nerve Na–K ATPase activity
and nerve conduction values in laboratory studies; however, no improvement was found in
electrophysiological parameters in humans. Their potential benefits are being able to inhibit
nerve damage. Thus, its administration is recommended at an early stage.
4.3. Vitamin addition
Vitamin treatment is often a non-specific therapy in neuropathy. Controlled studies show that
receiving thiamine, vitamin B12, pyridoxine, or pantothenic acid in diabetic neuropathy is of
no use [2,15].
4.4. ROS inhibitors
Alpha lipoic acid: High doses of alpha-lipoic acid were shown to have therapeutic efficacy in
the treatment of diabetic polyneuropathy and insulin resistance in experimental and clinical
Smart Drug Delivery System380
trials [2,9]. The patients (with symptomatic diabetic neuropathy) were given randomized IV
ALA 5 days a week (600 mg) or placebo in Sydney trials. After this treatment, a significant
improvement was noted in TSS of the patients treated with ALA compared to those given
placebo (5.7 vs. 1.8 points p ≤ 0.001) [16].
Nicotinamide: It inhibits oxidative stress–PARP activation cascade.
Resveratrol: It regulates NCV, diabetic neuropathic pain and inhibits NF-κB.
Routine: It prevents protein glycosylation.
Taurine: It reduces oxidative and nitrosative stress in Schwann cells. It reverses neurovascular
insufficiency and reduces increased pain sensitivity [9,17,18].
NO agonist: NO is one of the factors that play a role in the pathogenesis of DPN and l-arginine,
a NO agonist, was shown to increase Na–K ATPase activity [9].
Aldose reductase inhibitors: Many aldose reductase inhibitor drugs that are effective through the
polyol pathway were reported in the DPN treatment. Sorbinil, an aldose reductase inhibitor,
prevents sorbitol accumulation by inhibiting the enzyme aldose reductase in those with
diabetes and corrects neuronal dysfunction due to the change in the myoinositol content. It
leads to increase in NCV. Tolrestat is the other aldose reductase inhibitors and repairs impaired
NCV. Ponalrestat is effective in the delayed treatment of DPN. It normalizes NCV and prevents
the impaired neural induction of ornithine decarboxylase. Fidarestat induces the maturation
of the nerve fibers, stimulates the repair of nerve fibers, and stops the destruction of nerve
fibers. Epalrestat prevents the progression of MNCV, regulates the polyol pathway, and
suppresses the production of IGU [9].
PKC inhibitors: Ruboxistaurin, a PKC-β inhibitor, was found to be successful in treating
neuropathic sensory symptoms. It improves nerve fiber functions and microvascular blood
flow and increases life quality in those with DPN [9,19,20].
Immunosuppressive therapy: Inflammatory vasculopathy is thought to be important in the
pathogenesis of cases in which proximal diabetic neuropathy or amyotrophy was detected.
The treatment that is appropriate to the natural progress of diabetic amyotrophy and whose
validity was accepted is the treatment with immunomodulatory agents including IVIG or
corticosteroid. Better response is achieved with corticosteroid therapy and its cost of treatment
is less compared to IVIG. However, blood glucose regulation may be difficult with corticoste‐
roid. Starting with the dose of 0.75 mg/kg/day 3–4 times a week and discontinuing gradually
are recommended [21].
Pain treatment in diabetic neuropathy: Antidepressants, particularly tricyclic drugs, are the most
frequently used. Amitriptyline, imipramine, and nortriptyline may be used. Anticonvulsants
such as carbamazepine, gabapentin, pregabalin, and lamotrigine are among the treatment
options. Antiarrhythmics, mexiletine, and lidocaine are other pharmacological agents that are
used in case of unresponsiveness to other drugs. Capsaicin derived from paprika may be
preferred to as a topical agent for treating pain [21].
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Tricyclic antidepressants: A great percentage of patients were given at an average dose of 105
mg of amitriptyline or at an average dose of 111 mg desipramine in a double-blind, random‐
ized, placebo-controlled trial of the patients with painful diabetic peripheral neuropathy
(PDPN). Decrease in pain by 74%, 61%, and 41% was observed in patients who received
amitriptyline, desipramine, and placebo, respectively. Number needed to treat (NNT) is 2.1
(1.9–2.6) and number needed to harm (NNH) value is 2.8 for minor adverse events and 19 for
major adverse events. TCAs may promote orthostatic hypotension and may prolong QT (Q
wave and T wave) interval. An increase in the risk of sudden death has been reported with
TCAs by taking more than 100 mg amitriptyline or its equivalent [22].
Selective serotonin reuptake inhibitors (SSRIs): Alternatively, the patients are treated with SSRIs
because of many side effects of TCAs. These agents inhibit the presynaptic serotonin reuptake
selectively [9]. Unlike the tricyclics, SSRIs lack the postsynaptic receptor-blocking effect. NNT
to achieve 50% pain relief is 6.8 (3.4–441), and NNH is not known. While the benefit was
observed with paroxetine and citalopram, no benefit was obtained with fluoxetine [22].
Serotonin-norepinephrine reuptake inhibitors (SNRIs): The direction of the treatment of DPN was
shifted toward SNRIs because SSRIs are less effective in the treatment than TCAs and SNRIs
inhibit both serotonin and norepinephrine reuptake. Duloxetine and venlafaxine are examples
of SNRIs. Venlafaxine was argued to decrease the pain, and the effect on norepinephrine is
presumed to be more specific in a study in which high dose of venlafaxine was used. Dulox‐
etine is more effective in terms of the affinity in noradrenergic and serotonergic reuptake
inhibition. Many people were given duloxetine in the randomized, placebo-controlled studies
and 60 mg and 120 mg daily doses were reported to be effective in DPN [9,23,24].
Anticonvulsants: Antiepileptic drugs act by blocking sodium channels (felbamate, lamotrigine,
oxcarbazepine, topiramate, and zonisamide), potentiating the activity of GABA (tiagabine and
topiramate), blocking calcium channel (felbamate, lamotrigine, topiramate, and zonisamide),
antagonizing glutamate at N-methyl-d-aspartate (NMDA) α-receptors (felbamate), and
behaving as the antagonist of AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole) receptors
(felbamate and topiramate). Rational polytherapy by which we can obtain a synergistic effect
comes to the fore through understanding the mechanisms of these drugs. For example,
lamotrigine can be given for sodium channel blocking and felbamate may be added to
antagonize glutamate receptors or different mechanisms can be targeted with a single
medication, for instance, topiramate, and chance of success may be increased. It was reported
that a patient who was unresponsive to one of the antiepileptic drugs will respond to another
drug or combination treatment consisted of two or more drugs [25,26].
Topical capsaicin (capsaicin = 8-methyl-N-vanillyl-trans-6-nonenamide): C fibers use neuropeptide
P as a neurotransmitter, the reduction of axonal substance P causes pain relief. Storage of
substance P, which is released from sensory nerve terminals, finishes with the application of
capsaicin. Thus, the transmission of painful stimulus from peripheral nerve terminals is
reduced or completely eliminated. A significant improvement was observed in patients with
painful neuropathy treated with Capsaicin cream (0.075%) for 8 weeks. The treatment with
capsaicin should be limited to 8 weeks, because it is noted that adverse event may be observed
in sensory nerves at the end of this period. Eight percent capsaicin patch may be used in
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postherpetic neuralgia; however, it is contraindicated in diabetic neuropathy, because it
desensitizes the nociceptive sensory nerve endings, so it is reported that the risk of develop‐
ment of diabetic foot ulcers may be increased [25,27].
Topical lidocaine: Use of topical lidocaine in painful neuropathy is associated with postherpetic
neuralgia [16]. Lidocaine has been shown to be as effective as pregabalin in reducing pain
without causing the side effects in a multicenter, randomized, open-label, parallel group study
conducted by treating a group (n = 99) with 5% lidocaine for 2 weeks and treating another
group (n = 94) with pregabalin for 4 weeks. This therapy may be continued with oral mexiletine
in order to succeed. Relief of superficial pain caused by overstimulation is targeted with oral
mexiletine [25].
Acetyl-l-carnitine: It was reported that the pain and the slowed nerve conduction velocity were
improved, and nerve regeneration was increased with acetyl-l-carnitine in rats with strepto‐
zotocin-induced diabetic neuropathy. It was reported that the pain disappeared with acetyl-
l-carnitine, and the pain was resolved by prophylactic treatment in paclitaxel-treated rats [28].
5. Current therapeutic strategies in diabetic neuropathy
DPN is one of the most common symptoms of chronic neuropathic pain in clinical practice.
Various treatment methods are tried in patients with diabetic neuropathy. Tramadol, an
opioid, is a weak opioid analgesic used for reducing severe pain. It was reported that random‐
ized controlled trials for a period of 6 weeks were better than the placebo and symptomatic
relief continued for at least 6 months. The likelihood of side effects, as other opioid-like drugs,
is common. However, the development of drug tolerance and the development of addiction
with long-term therapy with tramadol are not common. NMDA receptors play a key role in
the sensitization of the neuropathic pain, but the use of these drugs is not widespread because
of their dose-limiting side effects [25]. NMDA receptor antagonists are used for modulation
of excitatory transmission in the primary afferent spinothalamic neuron synapses in recent
years. The pain ceases with the blockade of excitatory glutamatergic NMDA receptors in the
spinal cord. Dextromethorphan is one example of such painkiller medications. NMDA
receptor antagonists have been shown to be as effective as opioid analgesics for chronic pain
conditions. The diagnosis of diabetic neuropathy was made by a clinical evaluation (medical
history, motor, sensory, and reflex examination) and electrophysiological tests for 24 patients
with Type 2 diabetes and diabetic neuropathy. Pain complaints of the patients were assessed
with a VAS before and after the treatment. While a significant improvement in VAS scores was
observed in both treatment groups compared to the control group, the difference between
treatment groups was found to be significant. In conclusion, Memantine (NMDA receptor
antagonist) treatment provides an improvement in the treatment of neuropathic pain in
diabetic polyneuropathy [29].
Flavonoids, which many positive effects on human health were determined, have antioxidant,
anti-inflammatory, cholesterol lowering, antibacterial, antihyperglycemic, and antiallergic
features. It may be called P factor or P vitamin considering its capillary circulation regulating
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blood pressure lowering effects. The main one of these flavonoids is proantocianidin found in
grape seeds. The grape seed extract was given at the dose of 25 mg/kg and 50 mg/kg by oral
gavage for 6 weeks in a study in which diabetes was induced in BALB/C mice. The pain
threshold was measured using the Hot Plate Test, a thermal pain model, in these animals at
the end of second and sixth weeks. When the sciatic nerve and abdominal aorta tissue from
animals were examined histologically at the end of the study, hot plate measurements of the
groups received grape seed extract and the measurements between other groups were
considered significant. UCE (was seen to decrease damage in diabetes-induced micro and
macrovascular complications in histological evaluations [30].
5.1. DPP-4 inhibitors
Dipeptidyl peptidase-4 incretin hormones are secreted from intestinal endocrine cells. It plays
a key role in regulating blood glucose levels by stimulating glucose-dependent insulin
secretion, decreasing glucagon secretion, and slowing gastric emptying. DPP-4 inactivates
GLP-1 and glucose-dependent insulin tropical polypeptides (GIP) in vivo by destroying them.
These peptides are short lived in the circulation because they are destroyed by DPP-4.
Alogliptin is a DPP-4 inhibitor. The effects of this medication on vascular and neural compli‐
cations were evaluated in male Sprague–Dawley rats with STZ-induced diabetes. Alogliptin
was observed to regulate MNCV and thermal response latency after a 12-week treatment. No
improvement in the decrease in intraepidermal nerve fiber density was detected while SNCVs
of the mice were regulating. PKF 275-055, new analog of Vildagliptin, was given to STZ-
induced diabetic rats in the study of Bianchi et al., and it was found that it displays an anabolic
effect by preventing changes in nociceptive threshold, Na–K ATPase, and NCP. DPP-4
inhibitors were stated to prevent some neural and vascular complications associated with
diabetes in the studies conducted [9,31,32,33].
5.2. Cannabinoid CB1 receptor antagonists
Nabilone is a CB1 predominant receptor agonist. It was used in neuropathic pain based on the
anecdotal evidence and uncontrolled case series [34]. Pain reduction has been reported to occur
in 30% of the patients in a single center, randomized, double-blind, placebo-controlled, flexible
5-week study conducted by administering a dose ranges from 1 to 4 mg per day or placebo.
DPN symptoms disappeared, and their impaired sleep and standard of living were improved
in those received flexible dose. Nabilone is a well tolerated and successful adjuvant in patients
with DPN. Rimonabant is a CB1 receptor antagonist; it accelerates skin blood flow and
decreases TNF-α level in diabetic rats. It was stated that Rimonabant may be beneficial in the
treatment of DPN due to its micro and macro blood vessel protection and inflammatory effects
[9,34,35].
5.3. Natural products
Metanx: It is a product, used for the endothelial function disorder, containing l-methyl folate,
pyridoxal 5′ phosphate and methylcobalamin. It prevents endothelial NO synthesis, oxidative
stress in endothelium, and peripheral nerves. A significant improvement was noted in
numbness, tingling, pain, burning, sharp pain, and allodynia by giving Metanx to placebo-
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controlled diabetic neuropathy patients for 24 weeks. An increased emotional, social functions,
and vitality components of mental health were also detected. Side effects at less than 2% were
seen along this response. Generally, the side effects were rash and gastrointestinal disorders
and were no greater than the side effects seen with placebo [25].
Botulinum toxin: It was tried in trigeminal neuralgia and was reported that it has a long-term
antinociceptive effect in CTS without having electrophysiological repair [25].
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